<DOC>
	<DOC>NCT00963547</DOC>
	<brief_summary>This study will find the maximum tolerated dose of MK2206 in combination with both trastuzumab and trastuzumab/lapatinib in patients with HER2+ breast cancer and other solid tumors.</brief_summary>
	<brief_title>A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (2206-015)</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient has a histologically or cytologicallyconfirmed locally advanced or metastatic HER2+ solid tumor Female patients have a negative pregnancy test Patient is able to swallow tablets Patient has had chemotherapy, radiotherapy or biological therapy within 4 weeks of screening. Patients who were receiving trastuzumab and/or lapatinib prior to screening must be off both medications for 1 week prior to first dose of MK2206 if trastuzumab had been administered at 2 mg/kg weekly and 3 weeks if trastuzumab had been administered at 6 mg/kg weekly Patient has primary CNS tumor or known active CNS metastases Patient has a history or evidence of heart disease Patient has poorly controlled high blood pressure or diabetes Patient is pregnant or breastfeeding or is expecting to conceive or father children during the study Patient is HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Documented to be HER2+</keyword>
</DOC>